Oncolytic Virus Cancer Therapy Market Set for Rapid Growth Through 2036

Candel Therapeutics initiated the global pivotal Phase III AURORA trial in June 2026 to evaluate CAN-2409 with valacyclovir and continued pembrolizumab treatment in patients with metastatic non-squamous NSCLC following disease progression.

Meanwhile, CG Oncology reported encouraging Phase II results for cretostimogene grenadenorepvec plus gemcitabine in high-risk NMIBC in May 2026. Genelux also reported continued clinical progress for Olvi-Vec, with Phase III ovarian cancer topline data anticipated during the second half of 2026.

Oncolytic Virus Cancer Therapy Patient Pool and Market Opportunity

The addressable patient population represents another important component of the market opportunity. DelveInsight evaluates total cases of selected cancer types, the target patient pool for oncolytic virus therapies, and treated cases across major indications.

The analysis covers melanoma, biliary tract cancer, head and neck cancer, pancreatic cancer, NSCLC, hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, ovarian cancer, and other selected cancers.

The report evaluates the epidemiological landscape across the 7MM for the 2022–2036 study period. The growing burden of advanced and treatment-resistant cancers, combined with limitations associated with existing treatment approaches, may create opportunities for novel oncolytic virus therapies.

Future Outlook for Oncolytic Virus Cancer Therapy

The future development of the oncolytic virus cancer therapy market will depend on clinical efficacy, safety, regulatory progress, manufacturing capabilities, patient selection, and the ability of developers to demonstrate meaningful benefits in increasingly competitive oncology treatment landscapes.

As clinical programs mature, emerging therapies could expand the application of oncolytic viruses across multiple solid tumors. Combination strategies with immune checkpoint inhibitors, chemotherapy, targeted therapies, and other immunotherapies may further influence the treatment landscape.

Scope of the Oncolytic Virus Cancer Therapy Market Report

DelveInsight’s report provides comprehensive coverage of the oncolytic virus cancer therapy landscape, including patient population forecasts, therapeutics market size, pipeline analysis, market size and trends, market opportunities, unmet needs, KOL perspectives, market access, and reimbursement.

The report covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. It also evaluates key emerging therapies and their potential impact on future market dynamics.

The assessment can support stakeholders in understanding evolving treatment patterns, competitive developments, patient opportunities, and the broader commercial landscape surrounding oncolytic virus-based cancer therapies.

Learn more about the hydroxychloroquine oncolytic virus cancer therapy @ Oncolytic Virus Analytics -  https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Conclusion

The oncolytic virus cancer therapy market is entering an important phase of development, supported by advances in genetic engineering, expanding clinical pipelines, increasing interest in immuno-oncology, and a substantial population of patients with advanced or treatment-resistant cancers. Approved therapies such as IMLYGIC and DELYTACT have established clinical precedents, while newer candidates continue to expand across bladder cancer, melanoma, ovarian cancer, pancreatic cancer, NSCLC, and other malignancies. Continued clinical validation, regulatory progress, strategic collaborations, and combination-treatment research are expected to influence the market through 2036. As developers advance innovative viral platforms, oncolytic virus therapies may become an increasingly important component of the evolving cancer treatment landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com